Every cell depends on proteins to function and stay healthy. These proteins are made inside the cell from amino acids, but ...

Discover Mubadala Development, Abu Dhabi's sovereign wealth fund, committed to economic diversification and sustainable financial returns globally.

For many, the festive season conjures images of cosy gatherings, twinkling lights and joyful celebration. But beneath the ...

Studying one of the simplest animals, Stanford's Prakash Lab uncovered how it folds itself into complex shapes—revealing new ...

Innovation fails when every pilot starts from scratch; the chassis approach shows how to move fast with vendors while keeping ...

With the popularity of AI coding tools rising among some software developers, their adoption has begun to touch every aspect ...

Primary school students have been reading TikTok sensation Icebreaker, an enemies-to-lovers romance about a figure skater and ...

November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Learn more about whether Nurix Therapeutics, Inc. or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...